Prognosis of mucinous histology for patients with radically resected stage II and III colon cancer

Annals of Oncology

Volumn 23, Issue 1, 2012, Pages 135-141

  Catalano, V ^a   Loupakis, F ^b   Graziano, F ^a   Bisonni, R ^c   Torresi, U ^d   Vincenzi, B ^e   Mari, D ^f   Giordani, P ^a   Alessandroni, P ^a   Salvatore, L ^b   Fornaro, L ^b   Santini, D ^e   Baldelli, A M ^a   Rossi, D ^a   Giustini, L ^c   Silva, R R ^f   Falcone, A ^b   D'emidio, S ^a   Rocchi, M ^g   Luzi Fedeli, S ^a  

^a Azienda Ospedaliera 'Ospedali Riuniti Marche Nord'   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Ospedale 'A Murri'   (Italy)

^d Ospedale di Macerata   (Italy)

^e UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^f Medical Oncology   (Italy)

^g UNIVERSITY OF URBINO   (Italy)

Author keywords

Adjuvant chemotherapy; Colon cancer; Mucinous adenocarcinoma; Prognosis

Indexed keywords

BEVACIZUMAB; FLUOROPYRIMIDINE; IRINOTECAN; OXALIPLATIN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; COLON CANCER; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; LIVER METASTASIS; MAJOR CLINICAL STUDY; MALE; MUCINOUS CARCINOMA; MULTIPLE CYCLE TREATMENT; NONMUCINOUS ADENOCARCINOMA; OVERALL SURVIVAL; PERITONEUM METASTASIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 84855176448     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr062     Document Type: Article

References (38)

1. Green JB, Timmcke AE, Mitchell WT et al. Mucinous carcinoma: just another colon cancer? Dis Colon Rectum 1993; 36: 49-54.
2. Minsky BD, Mies C, Rich TA, Chaffey JT. Colloid carcinoma of the colon and rectum. Cancer 1987; 60: 3103-3112.
3. Consorti F, Lorenzotti A, Midiri G, Di Paola M. Prognostic significance of mucinous carcinoma of colon and rectum: a prospective case-control study. J Surg Oncol 2000; 73: 70-74.
4. Symonds DA, Vickery AL. Mucinous carcinoma of the colon and rectum. Cancer 1976; 37: 1891-1900.
5. Sundblad AS, Paz RA. Mucinous carcinoma of the colon and the rectum and their relation to polyps. Cancer 1982; 50: 2504-2509.
6. Hamilton SR, Aaltonen LA. Pathology and genetics: tumours of the digestive system. In Hamilton SR, Aaltonen LA (eds), World Health Organization Classification of Tumours, 3rd edition. Lyon, France: IARC 2000; 103-143.
7. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995; 75 (Suppl 1): 154-170.
8. Secco GB, Fardelli R, Campora E et al. Primary mucinous adenocarcinomas and signet-ring cell carcinomas of colon and rectum. Oncology 1994; 51: 30-34.
9. Wu CS, Tung SY, Chen PC, Kuo YC. Clinicopathological study of colorectal mucinous carcinoma in Taiwan: a multivariate analysis. J Gastroenterol Hepatol 1996; 11: 77-81.
10. Connelly JH, Robey-Cafferty SS, Cleary KR. Mucinous carcinomas of the colon and rectum. An analysis of 62 stage B and C lesions. Arch Pathol Lab Med 1991; 115: 1022-1025.
11. Umpleby HC, Ranson DL, Williamson RC. Peculiarities of mucinous colorectal carcinoma. Br J Surg 1985; 72: 715-718.
12. Compton C, Fenoglio-Preiser CM, Pettigrew N, Fielding LP. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88: 1739-1757.
13. Compton CC, Fielding LP, Burgart LJ et al. Prognostic factors in colorectal cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000; 124: 979-994.
14. Catalano V, Loupakis F, Graziano F et al. Mucinous histology predicts for poor response rate and overall survival of patients with colorectal cancer and treated with first-line oxaliplatin-and/or irinotecan-based chemotherapy. Br J Cancer 2009; 100: 881-887.
15. Negri FV, Wotherspoon A, Cunningham D et al. Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer. Ann Oncol 2005; 16: 1305-1310.
16. Du W, Mah JTL, Lee J et al. Incidence and survival of mucinous adenocarcinoma of the colorectum: a population-based study from an Asian country. Dis Colon Rectum 2004; 47: 78-85.
17. André T, Boni C, Navarro M et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109-3116.
18. Twelves C, Wong A, Nowacki MP et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704.
19. Haller DG, Catalano PJ, Macdonald JS et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678.
20. Quasar Collaborative Group, Gray R, Barnwell J et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029.
21. Benson AB III, Schrag D, Somerfield MR et al. American Society of Clinical Oncology recommendations on adjuvant therapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419.
22. AJCC. Colon cancer. In: Edge SB, Byrd DR, Compton CC et al. (eds), AJCC, 7th edition. New York: Springer 2010; 143-164.
23. Williams GT, Quirke P, Shepherd NA. Dataset for colorectal cancer, 2nd edition. London: The Royal College of Pathologists 2007. www.rcpath.org/resources/pdf/G049-ColorectalDataset-Sep07.pdf.
24. Sasaki O, Atkin WS, Jass JR. Mucinous carcinoma of the rectum. Histopathology 1987; 11: 259-272.
25. Halvorsen TB, Seim E. Influence of mucinous components on survival in colorectal adenocarcinomas: a multivariate analysis. J Clin Pathol 1988; 41: 1068-1072.
26. Okuno M, Ikehara T, Nagayama M et al. Mucinous colorectal carcinoma: clinical pathology and prognosis. Am Surg 1988; 54: 681-685.
27. Nozoe T, Anai H, Nasu S, Sugimachi K. Clinicopathological characteristics of mucinous carcinoma of the colon and rectum. J Surg Oncol 2000; 75: 103-107.
28. Kanemitsu Y, Kato T, Hirai T et al. Survival after curative resection for mucinous adenocarcinoma of the colorectum. Dis Colon Rectum 2003; 46: 160-167.
29. Kakar S, Aksoy S, Burgart L et al. Mucinous carcinoma of the colon: correlation of loss of mismatch repair enzymes with clinicopathologic features and survival. Mod Pathol 2004; 17: 696-700.
30. Song GA, Deng G, Bell I et al. Mucinous carcinomas of the colorectum have distinct molecular genetic characteristics. Int J Oncol 2005; 26: 745-750.
31. Sarli L, Bottarelli L, Azzoni C et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 2008; 15: 1429-1439.
32. Li M, Li JY, Zhao AL, Gu J. Colorectal cancer or colon and rectal cancer? Clinicopathological comparison between colonic and rectal carcinoma. Oncology 2007; 73: 52-57.
33. Manne U, Weiss HL, Grizzle WE. Racial differences in the prognostic usefulness of MUC1 and MUC2 in colorectal adenocarcinomas. Clin Cancer Res 2000; 6: 4017-4025.
34. Levin KE, Dozois RR. Epidemiology of large bowel cancer. World J Surg 1991; 15: 562-567.
35. Zhang H, Evertsson S, Sun X. Clinicopathological and genetic characteristics of mucinous carcinomas in the colorectum. Int J Oncol 1999; 14: 1057-1061.
36. Berovalis P, Harlaftis N. Prognostic significance of mucinous component in colorectal carcinoma. Tech Coloproctol 2004; 8 (Suppl): s123-s125.
37. Kondo T, Masuda H, Abe Y, Takayama T. Two subtypes in colorectal mucinous carcinoma in relation to microsatellite instability. Hepatogastroenterology 2002; 49: 660-663.
38. Liu XP, Sato T, Oga A et al. Two subtypes of mucinous colorectal carcinoma characterized by laser scanning cytometry and a comparative genomic hybridization. Int J Oncol 2004; 25: 615-625.